Polivy - direct healthcare professional communication (DHPC)

polatuzumab vedotin

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Polivy (polatuzumab vedotin) 140 mg powder for concentrate for solution for injection: Important information on plastic vial flip-off cap colour

Key facts

• Medicine name:
  Polivy
• Active substance:
  polatuzumab vedotin
• Therapeutic area (MeSH):
  Lymphoma, B-Cell
• Procedure number:
  EMEA/H/C/004870
• DHPC type:
  Quality defect
• Human ATC codes:
  L01FX06